Read this first
This is plain-language harm-reduction information, not medical advice. Peptides discussed here are research compounds; most are not approved for human use. People will use them either way — we would rather they have the facts.
What it is
TB-500 is a synthetic peptide that mimics part of Thymosin Beta-4, a naturally occurring protein involved in cell migration, blood vessel growth and tissue repair.
It is widely used in equestrian sport (and banned there) for injury recovery. In humans the data is mostly anecdotal.
History
Thymosin Beta-4 itself was isolated from the thymus in the 1960s. The shorter active TB-500 fragment has been studied since the 1980s and entered grey-market athletic use in the 2000s.
How it works
Acts on actin, a protein involved in cell movement. Helps cells migrate to damaged areas faster, which speeds up the early phase of tissue repair.
Dosage
- Loading phase: 2–2.5 mg twice weekly for 4–6 weeks.
- Maintenance: 2–2.5 mg once weekly or every two weeks.
- Some users dose smaller amounts daily; the evidence either way is thin.
How it is taken
- Subcutaneous belly injection with an insulin pin.
- Site of injection does not appear to matter — TB-500 distributes systemically.
How to reconstitute
- A 5 mg vial with 2 ml of BAC water gives 2.5 mg/ml. A full 2.5 mg dose is 100 units on a 1 ml insulin syringe.
- Reconstitute gently, store in fridge, do not freeze.
How it should arrive
Sealed vial with white powder or thin white puck. Vacuum-sealed cap; needle should slightly pull in when pierced.
How it should look once reconstituted
Clear, colourless, no particles.
What to expect, and when
- Most users report nothing for the first 1–2 weeks.
- Effects on chronic injuries (3+ weeks): improved range of motion, less stiffness, gradual healing.
- Acute injury anecdotes (weeks 4–6): faster return to function than expected.
Side effects
- Generally well tolerated.
- Mild head rush, lightheadedness, occasional fatigue after injection.
- Some users report temporary lethargy in the loading phase.
Risks
- Same theoretical cancer-promotion concern as BPC-157 — TB-4 is involved in angiogenesis. No evidence of human cancer risk; also no long-term studies.
- WADA prohibited.
Potential gains
- Anecdotal: faster recovery from muscle, tendon, ligament injuries.
- Some users report improved flexibility and joint comfort.
Other useful information
Pairs with BPC-157 in many community "healing stacks". Costs more than BPC-157 per dose, but you typically inject it less often.
Looking for a goal-based recommendation?
Try the Find your goal tool — answer five short questions and get peptides matched to what you actually want.